<DOC>
	<DOCNO>NCT02953808</DOCNO>
	<brief_summary>This first study GSK2315698 administer Japanese population . The primary objective study investigate safety tolerability , pharmacokinetics , pharmacodynamics single intravenous infusion healthy subject . This single center , double-blind , randomize , placebo-controlled , dose-ascending study . Subjects Cohort 1 attend 3 dosing session , randomize one 3 group . Each group receive GSK2315698 Placebo define sequence . The dose level GSK2315698 set 10 milligram ( mg ) per hour ( hr ) , 20 mg/hr , 40 mg/hr , administer 1 hour . Dosing session 1 2 , dose session 2 3 , separate washout period least 8 10 day , respectively . Subjects Cohort 2 attend single dosing session , randomize receive either GSK2315698 20 mg/hr Placebo , period 15 hour . A sufficient number subject randomize 18 subject ( 9 cohort ) complete study . The duration participation subject study approximately 59 day .</brief_summary>
	<brief_title>Phase 1 Study GSK2315698 Healthy Japanese Subjects</brief_title>
	<detailed_description />
	<mesh_term>Amyloidosis</mesh_term>
	<criteria>Participant must 20 64 year age inclusive , time signing inform consent Participants overtly healthy determine medical evaluation include medical history , physical examination , laboratory test , cardiac monitoring . A subject clinical abnormality laboratory parameter ( ) is/are specifically list inclusion exclusion criterion , outside reference range population study may include investigator consultation Medical Monitor require agree find unlikely introduce additional risk factor interfere study procedure Peripheral vein suitable venous blood sample cannulation Body weight &gt; =50 kilogram ( kg ) body mass index ( BMI ) within range 18.524.9 kg per meter ( ) square ( inclusive ) Male : A Japanese male participant must agree use contraception treatment period follow visit Capable give sign informed consent History presence cardiovascular , respiratory , hepatic , renal , gastrointestinal , endocrine , hematological , neurological disorder capable significantly alter absorption , metabolism , elimination drug ; constitute risk take study treatment ; interfere interpretation data Clinically abnormal hypotonia hyperpiesia determine investigator Previous surgical procedure upper digestive tract include cholecystectomy ( gallbladder removal ) , and/or cholelithotomy ( gallstone removal ) Alanine Aminotransferase ( ALT ) &gt; 1.5 multiplied upper limit normal ( ULN ) Bilirubin &gt; 1.5 time ULN ( isolated bilirubin &gt; 1.5 time ULN acceptable bilirubin fractionate direct bilirubin &lt; 35 % ) Current chronic history liver disease , know hepatic biliary abnormality ( exception Gilbert 's syndrome asymptomatic gallstone ) QTcF &gt; 450 millisecond ( msec ) QTcF either machineread manually overread . The specific formula use determine eligibility discontinuation individual subject determine prior initiation study . In word , several different formula use calculate correct QT interval ( QTc ) individual subject low QTc value use include discontinue subject trial . For purpose data analysis , QTcF , another QT correction formula , composite available value QTc use Past intend use overthecounter prescription medication include herbal medication within 14 day prior dose . Specific studydefined medication may allow History donation blood blood product &gt; =400 mL within 3 month &gt; =200 mL within 1 month prior screen Exposure 4 new chemical entity within 12 month prior first dose day Current enrollment past participation within last 3 month , 5 halflives twice duration biological effect investigational product ( whichever longer ) sign consent clinical study involve investigational study treatment type medical research The subject positive Serological test syphilis ( Rapid plasma reagin test [ RPR ] Treponema pallidum Latex Agglutination [ TPLA ] ) , Human immunodeficiency virus ( HIV ) antigen/antibody , Hepatitis B surface antigen ( HbsAg ) , Hepatitis C virus ( HCV ) antibody , Human Tcell lymphotropic virus type 1 ( HTLV1 ) antibody screen Positive prestudy drug screen Regular use know drug abuse Regular alcohol consumption within 6 month prior study defined average weekly intake &gt; 14 unit male . One unit equivalent 350 mL beer , 150 mL wine 45 mL 80 proof distil spirit Smoking history regular use tobacco nicotinecontaining product within 6 month prior screen ; Sensitivity study treatment , component thereof , drug allergy , opinion investigator Medical Monitor , contraindicate participation study</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>GSK2315698</keyword>
	<keyword>Dose-ascending</keyword>
	<keyword>Systemic amyloidosis</keyword>
</DOC>